- Home
- TOPS vs INKT Comparison
TOPS vs INKT Comparison
Compare TOPS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- INKT
- Stock Information
- Founded
- TOPS 2000
- INKT 2017
- Country
- TOPS Greece
- INKT United States
- Employees
- TOPS N/A
- INKT N/A
- Industry
- TOPS Marine Transportation
- INKT Medicinal Chemicals and Botanical Products
- Sector
- TOPS Consumer Discretionary
- INKT Health Care
- Exchange
- TOPS Nasdaq
- INKT Nasdaq
- Market Cap
- TOPS 27.4M
- INKT 28.9M
- IPO Year
- TOPS 2004
- INKT 2021
- Fundamental
- Price
- TOPS $5.90
- INKT $7.20
- Analyst Decision
- TOPS
- INKT Strong Buy
- Analyst Count
- TOPS 0
- INKT 2
- Target Price
- TOPS N/A
- INKT $37.50
- AVG Volume (30 Days)
- TOPS 122.8K
- INKT 14.8K
- Earning Date
- TOPS 08-08-2025
- INKT 08-12-2025
- Dividend Yield
- TOPS N/A
- INKT N/A
- EPS Growth
- TOPS N/A
- INKT N/A
- EPS
- TOPS 1.09
- INKT N/A
- Revenue
- TOPS $86,127,000.00
- INKT N/A
- Revenue This Year
- TOPS $9.90
- INKT N/A
- Revenue Next Year
- TOPS N/A
- INKT N/A
- P/E Ratio
- TOPS $5.41
- INKT N/A
- Revenue Growth
- TOPS 3.83
- INKT N/A
- 52 Week Low
- TOPS $5.00
- INKT $4.56
- 52 Week High
- TOPS $11.47
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- TOPS 47.25
- INKT 47.64
- Support Level
- TOPS $5.10
- INKT $6.80
- Resistance Level
- TOPS $6.00
- INKT $7.55
- Average True Range (ATR)
- TOPS 0.50
- INKT 0.37
- MACD
- TOPS -0.06
- INKT -0.03
- Stochastic Oscillator
- TOPS 39.02
- INKT 25.32
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.